Acetaminophen preparation, and method for producing same

11458,102

16/761317

November 08, 2018

A preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent dissolution properties, preferable hardness and high drug content uniformity and a manufacturing method thereof. Acetaminophen has a preset particle size and is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed, manufacturing efficiency can be elevated and the cost for manufacturing is also reduced. Thus, an acetaminophen preparation having improved administrability, for example, a reduced size and a manufacturing method thereof are highly useful.

NIPPON ZOKI PHARMACEUTICAL CO., LTD. (Osaka, JP)

NIPPON ZOKI PHARMACEUTICAL CO., LTD. (Osaka, JP)

1. A method for manufacturing a tablet comprising acetaminophen by a dry direct compression method, comprising: (a) adding water to an unpulverized acetaminophen having a particle size distribution in which d 10 is in a range of 5 μm to 150 μm and d 90 is in a range of 200 μm to 1800 μm as measured by a laser-diffraction method; (b) blending at least one additive selected from the group consisting of an excipient, dispersant, and disintegrating agent; (c) blending a lubricant; (d) compacting a mixture from step (c) to produce a tablet; and carrying out deagglomeration and sizing at least one time in step (a) to step (c) to disperse and adhere the at least one additive to the surfaces of acetaminophen particles, wherein the excipient is at least one selected from the group consisting of a sugar, a sugar alcohol, microcrystalline cellulose, powdered cellulose, corn starch, potato starch, partly pregelatinized starch, sodium carboxymethyl starch, dextrin, β-cyclodextrin, carmellose sodium, anhydrous silicic acid, hydrated silicon dioxide, silicon dioxide, precipitated calcium carbonate, anhydrous dibasic calcium phosphate, magnesium oxide, titanium oxide, calcium lactate, magnesium aluminate metasilicate, synthetic hydrotalcite, talc, and kaolin, wherein the dispersant is at least one selected from the group consisting of hydrated silicon dioxide, anhydrous silicic acid, synthetic aluminum silicate, alumina magnesium hydroxide, magnesium aluminometasilicate, and dibasic calcium phosphate fine granulated, wherein the disintegrating agent is at least one selected from the group consisting of carboxymethylcellulose, carboxymethyl starch, crospovidone, low substituted hydroxypropylcellulose, low-substituted sodium hydroxymethyl starch, partly pregelatinized starch, corn starch, potato starch, alginic acid, and bentonite, wherein the lubricant is at least one selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, talc, sucrose esters of fatty acids, glycerol esters of fatty acids, a hydrogenated oil, polyethylene glycol, dimethyl polysiloxane, carnauba wax, sodium lauryl sulfate, yellow beeswax, and white beeswax, and wherein an addition ratio of the water is in a range of 0.5 to 3% by weight relative to 100% by weight of the tablet.

2. The manufacturing method according to claim 1 , wherein a content of the acetaminophen in the tablet is in a range of 75 to 95% by weight relative to 100% by weight of the tablet.

3. The manufacturing method according to claim 1 , wherein a content of the acetaminophen in the tablet is in an amount in a range of 85 to 95% by weight relative to 100% by weight of the tablet.

4. The manufacturing method according to claim 1 , wherein a content of the acetaminophen in the tablet is in an amount in a range of 90 to 93% by weight relative to 100% by weight of the tablet.

5. The manufacturing method according to claim 1 , wherein, in the particle size distribution of the unpulverized acetaminophen, d 10 is in a range of 10 μm to 150 μm and d 90 is in a range of 250 μm to 1600 μm.

6. The manufacturing method according to claim 1 , wherein, in the particle size distribution of the unpulverized acetaminophen, d 10 is in a range of 12 μm to 100 μm and d 90 is in a range of 280 μm to 1450 μm.

7. The manufacturing method according to claim 1 , wherein the dispersant is hydrated silicon dioxide or anhydrous silicic acid.

8. The manufacturing method according to claim 1 , wherein a content of the dispersant in the tablet is in an amount in a range of 0.1 to 3% by weight relative to 100% by weight of the tablet.

9. The manufacturing method according to claim 1 , wherein the excipient is microcrystalline cellulose.

10. The manufacturing method according to claim 1 , wherein a content of the excipient in the tablet is in an amount in a range of 0.5 to 10% by weight relative to 100% by weight of the tablet.

11. The manufacturing method according to claim 1 , wherein the disintegrating agent is low-substituted hydroxypropylcellulose or crospovidone.

12. The manufacturing method according to claim 1 , wherein a content of the disintegrating agent in the tablet is in an amount in a range of 1 to 10% by weight relative to 100% by weight of the tablet.

13. A tablet prepared by the method according to claim 1 , the tablet comprising: the acetaminophen as an active ingredient in an amount of 75 to 95% by weight relative to 100% by weight of the tablet, and the dispersant, wherein a hardness of the tablet is higher than 46 N.

5370878 December 1994 Shah
5733578 March 1998 Hunter
5965166 October 1999 Hunter
6852336 February 2005 Hunter
8106100 January 2012 Kakizawa
9029429 May 2015 Bracht
10172806 January 2019 Yada
10426838 October 2019 Honda
10632074 April 2020 Uramatsu
10888520 January 2021 Ichikawa
1 161 941 December 2001
H10-506412 June 1998
2002-060338 February 2002
2003-081876 March 2003
2013-216610 October 2013
97/017947 May 1997
00/54752 September 2000
2017/162852 September 2017

A Guidebook to Particle Size Analysis. Ed. Horiba Instruments Inc., 2017, 34 pages. (Year: 2017). cited by examiner
Terashita et al.; “Preparation of Antipyretic Analgesic by Direct Compression and Its Evaluation;” Chem. Pharm. Bull.; 2002; pp. 1542-1549; vol. 50, No. 12. cited by applicant
Dec. 25, 2018 Search Report issued in International Patent Application No. PCT/JP2018/041539. cited by applicant
May 12, 2020 International Preliminary Repod on Patentability issued in International Patent Application No. PCT/JP2018/041539. cited by applicant
Jul. 28, 2021 Supplementary Extended European Search Report issued in European Patent Application No. 18875644.9. cited by applicant
Ghoroi et al. “Multi-faceted characterization of pharmaceutical powders to discern the influence of surface modification,” Powder Technology, vol. 236, May 22, 2012, pp. 63-74. cited by applicant
Luczak et al. “Polymorph stabilization in processed acetaminophen powders,” Powder Technology, vol. 236, May 29, 2012, pp. 52-62. cited by applicant

edspgr.11458102